https://orcid.org/0000-0001-6328-1741
Abstract
Relapse and refractory T-cell acute lymphoblastic leukemia (T-ALL) has a poor prognosis, and new combination therapies are sorely needed. Here, we used an ex vivo high-throughput screening platform to identify drug combinations that kill zebrafish T-ALL and then validated top drug combinations for preclinical efficacy in human disease. This work uncovered potent drug synergies between AKT/mTORC1 (mammalian target of rapamycin complex 1) inhibitors and the general tyrosine kinase inhibitor dasatinib. Importantly, these same drug combinations effectively killed a subset of relapse and dexamethasone-resistant zebrafish T-ALL. Clinical trials are currently underway using the combination of mTORC1 inhibitor temsirolimus and dasatinib in other pediatric cancer indications, leading us to prioritize this therapy for preclinical testing. This combination effectively curbed T-ALL growth in human cell lines and primary human T-ALL and was well tolerated and effective in suppressing leukemia growth in patient-derived xenografts (PDX) grown in mice. Mechanistically, dasatinib inhibited phosphorylation and activation of the lymphocyte-specific protein tyrosine kinase (LCK) to blunt the T-cell receptor (TCR) signaling pathway, and when complexed with mTORC1 inhibition, induced potent T-ALL cell killing through reducing MCL-1 protein expression. In total, our work uncovered unexpected roles for the LCK kinase and its regulation of downstream TCR signaling in suppressing apoptosis and driving continued leukemia growth. Analysis of a wide array of primary human T-ALLs and PDXs grown in mice suggest that combination of temsirolimus and dasatinib treatment will be efficacious for a large fraction of human T-ALLs.
Subjects:
Lymphoid Neoplasia
Key Points
Temsirolimus mTORC1 inhibitor and dasatinib kinase inhibitor synergize to kill a large fraction of xenograft and primary human T-ALL.
The LCK kinase, which is inhibited by dasatinib, has unexpected roles in regulating TCR signaling pathways to drive continued T-ALL growth.
Subjects:
Lymphoid Neoplasia
References
1.
Hao
T
, Li-Talley
M
, Buck
A
, Chen
W
. An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States
. Sci Rep
. 2019
;9
(1
):12070
.2.
Van Vlierberghe
P
, Ferrando
A
. The molecular basis of T cell acute lymphoblastic leukemia
. J Clin Invest
. 2012
;122
(10
):3398
-3406
.3.
Girardi
T
, Vicente
C
, Cools
J
, De Keersmaecker
K
. The genetics and molecular biology of T-ALL
. Blood
. 2017
;129
(9
):1113
-1123
.4.
Tremblay
CS
, Hoang
T
, Hoang
T
. Early T cell differentiation lessons from T-cell acute lymphoblastic leukemia
. Prog Mol Biol Transl Sci
. 2010
;92
(C
):121
-156
.5.
Gutierrez
A
, Sanda
T
, Grebliunaite
R
, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia
. Blood
. 2009
;114
(3
):647
-650
.6.
Lonetti
A
, Cappellini
A
, Bertaina
A
, et al. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway
. J Hematol Oncol
. 2016
;9
(1
):114
.7.
Lynch
JT
, McEwen
R
, Crafter
C
, et al. Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen
. Oncotarget
. 2016
;7
(16
):22128
-22139
.8.
Blackburn
JS
, Liu
S
, Wilder
JL
, et al. Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation
. Cancer Cell
. 2014
;25
(3
):366
-378
.9.
Liu
Y
, Easton
J
, Shao
Y
, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
. Nat Genet
. 2017
;49
(8
):1211
-1218
.10.
De Smedt
R
, Morscio
J
, Goossens
S
, Van Vlierberghe
P
. Targeting steroid resistance in T-cell acute lymphoblastic leukemia
. Blood Rev
. 2019
;38
:100591
.11.
Clappier
E
, Gerby
B
, Sigaux
F
, et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse
. J Exp Med
. 2011
;208
(4
):653
-661
.12.
Cantley
AM
, Welsch
M
, Ambesi-Impiombato
A
, et al. Small molecule that reverses dexamethasone resistance in T-cell acute lymphoblastic leukemia (T-ALL)
. ACS Med Chem Lett
. 2014
;5
(7
):754
-759
.13.
Piovan
E
, Yu
J
, Tosello
V
, et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia
. Cancer Cell
. 2013
;24
(6
):766
-776
.14.
Chiang
YJ
, Hodes
RJ
. T-cell development is regulated by the coordinated function of proximal and distal Lck promoters active at different developmental stages
. Eur J Immunol
. 2016
;46
(10
):2401
-2408
.15.
Palacios
EH
, Weiss
A
. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation
. Oncogene
. 2004
;23
(48
):7990
-8000
.16.
van Oers
NSC
, Lowin-Kropf
B
, Finlay
D
, Connolly
K
, Weiss
A
. Alpha beta T cell development is abolished in mice lacking both Lck and Fyn protein tyrosine kinases
. Immunity
. 1996
;5
(5
):429
-436
.17.
Gascoigne
NRJ
, Casas
J
, Brzostek
J
, Rybakin
V
. Initiation of TCR phosphorylation and signal transduction
. Front Immunol
. 2011
;2
:72
.18.
Love
PE
, Hayes
SM
. ITAM-mediated signaling by the T-cell antigen receptor
. Cold Spring Harb Perspect Biol
. 2010
;2
(6
):a002485
.19.
Cordo’
V
, van der Zwet
JCG
, Canté-Barrett
K
, Pieters
R
, Meijerink JPP
. T-cell acute lymphoblastic leukemia: a roadmap to targeted therapies
. Blood Cancer Discov
. 2020
;2
(1
):19
-31
.20.
van Dongen
JJ
, Krissansen
GW
, Wolvers-Tettero
IL
, et al. Cytoplasmic expression of the CD3 antigen as a diagnostic marker for immature T-cell malignancies
. Blood
. 1988
;71
(3
):603
-612
.21.
Gocho
Y
, Yang
JJ
. Genetic defects in hematopoietic transcription factors and predisposition to acute lymphoblastic leukemia
. Blood
. 2019
;134
(10
):793
-797
.22.
Cordo’
V
, Meijer
MT
, Hagelaar
R
, et al. Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies
. Nat. Commun
. 2022
;13
(1
):1
-13
.23.
Goldsmith
MA
, Weiss
A
. Isolation and characterization of a T-lymphocyte somatic mutant with altered signal transduction by the antigen receptor
. Proc Natl Acad Sci USA
. 1987
;84
(19
):6879
-6883
.24.
Straus
DB
, Weiss
A
. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor
. Cell
. 1992
;70
(4
):585
-593
.25.
Vico-Barranco
I
, Arbulo-Echevarria
MM
, Serrano-García
I
, et al. A novel, LAT/Lck double deficient T cell subline J.CaM1.7 for combined analysis of early TCR signaling
. Cells
. 2021
;10
(2
):1
-20
.26.
Serafin
V
, Capuzzo
G
, Milani
G
, et al. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia
. Blood
. 2017
;130
(25
):2750
-2761
.27.
Garcia
EG
, Veloso
A
, Oliveira
ML
, et al. PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis
. Leukemia
. 2020
;35
(3
):679
-690
.28.
Trinquand
A
, Dos Santos
NR
, Tran Quang
C
, et al. Triggering the TCR developmental checkpoint activates a therapeutically targetable tumor suppressive pathway in T-cell leukemia
. Cancer Discov
. 2016
;6
(9
):972
-985
.29.
Evangelisti
C
, Chiarini
F
, McCubrey
JA
, Martelli
AM
. Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: an update
. Int J Mol Sci
. 2018
;19
(7
):E1878
.30.
Rheingold
SR
, Tasian
SK
, Whitlock
JA
, et al. A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children’s Oncology Group study (ADVL1114)
. Br J Haematol
. 2017
;177
(3
):467
-474
.31.
Blackburn
JS
, Liu
S
, Langenau
DM
. Quantifying the frequency of tumor-propagating cells using limiting dilution cell transplantation in syngeneic zebrafish
. J Vis Exp
. 2011
;53
:e2790
.32.
Boulos
N
, Mulder
HL
, Calabrese
CR
, et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia
. Blood
. 2011
;117
(13
):3585
-3595
.33.
Teachey
DT
, Obzut
DA
, Cooperman
J
, et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL
. Blood
. 2006
;107
(3
):1149
-1155
.34.
Schneider
CA
, Rasband
WS
, Eliceiri
KW
. NIH Image to ImageJ: 25 years of image analysis
. Nat Methods
. 2012
;9
(7
):671
-675
.35.
Karjalainen
R
, Pemovska
T
, Popa
M
, et al. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML
. Blood
. 2017
;130
(6
):789
-802
.36.
Yadav
B
, Pemovska
T
, Szwajda
A
, et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
. Sci Rep
. 2014
;4
(1
):1
-10
.37.
Ianevski
A
, Giri
AK
, Aittokallio
T
. SynergyFinder 2.0: visual analytics of multi-drug combination synergies
. Nucleic Acids Res
. 2020
;48
(W1
):W488
-W493
.38.
Nagel
S
, Venturini
L
, Meyer
C
, et al. Multiple mechanisms induce ectopic expression of LYL1 in subsets of T-ALL cell lines
. Leuk Res
. 2010
;34
(4
):521
-528
.39.
Kalender Atak
Z
, De Keersmaecker
K
, Gianfelici
V
, et al. High accuracy mutation detection in leukemia on a selected panel of cancer genes
. PLoS One
. 2012
;7
(6
):e38463
.40.
Elwood
NJ
, Green
AR
, Melder
A
, Begley
CG
, Nicola
N
. The SCL protein displays cell-specific heterogeneity in size
. Leukemia
. 1994
;8
(1
):106
-114
.41.
Drexler
HG
. The leukemia-lymphoma cell line factsbook: Academic Press
; 2000
.42.
Mansour
MR
, Abraham
BJ
, Anders
L
, et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element
. Science
. 2014
;346
(6215
):1373
-1377
.43.
Ngoc
PCT
, Tan
SH
, Tan
TK
, et al. Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia
. Leukemia
. 2018
;32
(10
):2138
-2151
.44.
Shaw
TI
, Dong
L
, Tian
L
, et al. Integrative network analysis reveals USP7 haploinsufficiency inhibits E-protein activity in pediatric T-lineage acute lymphoblastic leukemia (T-ALL)
. Sci Rep
. 2021
;11
(1
):1
-12
.45.
Ghandi
M
, Huang
FW
, Jané-Valbuena
J
, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia
. Nature
. 2019
;569
(7757
):503
-508
.46.
Koskela
HLM
, Eldfors
S
, Ellonen
P
, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia
. N Engl J Med
. 2012
;366
(20
):1905
-1913
.47.
Dufva
O
, Pölönen
P
, Brück
O
, et al. Immunogenomic landscape of hematological malignancies
. Cancer Cell
. 2020
;38
(3
):424
-428
.48.
Laukkanen
S
, Oksa
L
, Nikkilä
A
, et al. SIX6 is a TAL1-regulated transcription factor in T-ALL and associated with inferior outcome
. Leuk Lymphoma
. 2020
;61
(13
):3089
-3100
.49.
Blackburn
JS
, Liu
S
, Raiser
DM
, et al. Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency
. Leukemia
. 2012
;26
(9
):2069
-2078
.50.
Lobbardi
R
, Pinder
J
, Martinez-Pastor
B
, et al. TOX regulates growth, DNA repair, and genomic instability in T-cell acute lymphoblastic leukemia
. Cancer Discov
. 2017
;7
(11
):1336
-1353
.51.
Feng
H
, Stachura
DL
, White
RM
, et al. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation
. Cancer Cell
. 2010
;18
(4
):353
-366
.52.
Mansour
MR
, He
S
, Li
Z
, et al. JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia
. J Exp Med
. 2018
;215
(7
):1929
-1945
.53.
Ridges
S
, Heaton
WL
, Joshi
D
, et al. Zebrafish screen identifies novel compound with selective toxicity against leukemia
. Blood
. 2012
;119
(24
):5621
-5631
.54.
Li
Z
, He
S
, Look
AT
. The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells
. Leukemia
. 2019
;33
(1
):262
-266
.55.
Gutierrez
A
, Pan
L
, Groen
RWJ
, et al. Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia
. J Clin Invest
. 2014
;124
(2
):644
-655
.56.
Garcia
EG
, Iyer
S
, Garcia
SP
, et al. Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia
. Leukemia
. 2018
;32
(8
):1860
-1865
.57.
Borga
C
, Foster
CA
, Iyer
S
, Garcia
SP
, Langenau
DM
, Frazer
JK
. Molecularly distinct models of zebrafish Myc-induced B cell leukemia
. Leukemia
. 2019
;33
(2
):559
-562
.58.
Langenau
DM
, Traver
D
, Ferrando
AA
, et al. Myc-induced T cell leukemia in transgenic zebrafish
. Science
. 2003
;299
(5608
):887
-890
.59.
Borga
C
, Park
G
, Foster
C
, et al. Simultaneous B and T cell acute lymphoblastic leukemias in zebrafish driven by transgenic MYC: implications for oncogenesis and lymphopoiesis
. Leukemia
. 2019
;33
(2
):333
-347
.60.
Gocho
Y
, Liu
J
, Hu
J
, et al. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia
. Nat Cancer
. 2021
;2
(3
):284
-299
.61.
Schade
AE
, Schieven
GL
, Townsend
R
, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation
. Blood
. 2008
;111
(3
):1366
-1377
.62.
Lee
KC
, Ouwehand
I
, Giannini
AL
, Thomas
NS
, Dibb
NJ
, Bijlmakers
MJ
. Lck is a key target of imatinib and dasatinib in T-cell activation
. Leukemia
. 2010
;24
(4
):896
-900
.63.
Suryadevara
CM
, Desai
R
, Farber
SH
, et al. Preventing Lck activation in CAR T cells confers Treg resistance but requires 4-1BB signaling for them to persist and treat solid tumors in nonlymphodepleted hosts
. Clin Cancer Res
. 2019
;25
(1
):358
-368
.64.
Rossy
J
, Williamson
DJ
, Gaus
K
. How does the kinase Lck phosphorylate the T cell receptor? Spatial organization as a regulatory mechanism
. Front Immunol
. 2012
;3
:167
.65.
Hwang
JR
, Byeon
Y
, Kim
D
, Park
SG
. Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development
. Exp Mol Med
. 2020
;52
(5
):750
-761
.66.
Prokop
A
, Wieder
T
, Sturm
I
, et al. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo
. Leukemia
. 2000
;14
(9
):1606
-1613
.67.
Egle
A
, Harris
AW
, Bouillet
P
, Cory
S
. Bim is a suppressor of Myc-induced mouse B cell leukemia
. Proc Natl Acad Sci USA
. 2004
;101
(16
):6164
-6169
.68.
Bachmann
PS
, Piazza
RG
, Janes
ME
, et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition
. Blood
. 2010
;116
(16
):3013
-3022
.69.
Gratiot-Deans
J
, Merino
R
, Nuñez
G
, Turka
LA
. Bcl-2 expression during T-cell development: early loss and late return occur at specific stages of commitment to differentiation and survival
. Proc Natl Acad Sci USA
. 1994
;91
(22
):10685
-10689
.70.
Peirs
S
, Matthijssens
F
, Goossens
S
, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia
. Blood
. 2014
;124
(25
):3738
-3747
.71.
Ruvolo
PP
, Deng
X
, May
WS
. Phosphorylation of Bcl2 and regulation of apoptosis
. Leukemia
. 2001
;15
(4
):515
-522
.72.
Inuzuka
H
, Shaik
S
, Onoyama
I
, et al. SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction
. Nature
. 2011
;471
(7336
):104
-109
.73.
Choudhary
GS
, Al-Harbi
S
, Mazumder
S
, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
. Cell Death Dis
. 2015
;6
(1
):e1593
.74.
Suryani
S
, Carol
H
, Chonghaile
TN
, et al. Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts
. Clin Cancer Res
. 2014
;20
(17
):4520
-4531
.75.
Hara
J
, Benedict
SH
, Champagne
E
, Mak
TW
, Minden
M
, Gelfand
EW
. Comparison of T cell receptor alpha, beta, and gamma gene rearrangement and expression in T cell acute lymphoblastic leukemia
. J Clin Invest
. 1988
;81
(4
):989
-996
.76.
Laukkanen
S
, Grönroos
T
, Pölönen
P
, et al. In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL
. Blood Cancer J
. 2017
;7
(9
):e604
.77.
Sandberg
Y
, Verhaaf
B
, van Gastel-Mol
EJ
, et al. Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes
. Leukemia
. 2007
;21
(2
):230
-237
.78.
Crombet
O
, Lastrapes
K
, Zieske
A
, Morales-Arias
J
. Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification
. Pediatr Blood Cancer
. 2012
;59
(2
):333
-334
.79.
Soverini
S
, Colarossi
S
, Gnani
A
, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
. Haematologica
. 2007
;92
(3
):401
-404
.80.
Wöhrle
FU
, Halbach
S
, Aumann
K
, et al. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors
. Leukemia
. 2013
;27
(1
):118
-129
.81.
Shi
Y
, Beckett
MC
, Blair
HJ
, et al. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia
. Haematologica
. 2021
;106
(4
):1056
-1066
.82.
Frismantas
V
, Dobay
MP
, Rinaldi
A
, et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia
. Blood
. 2017
;129
(11
):e26
-e37
.83.
Dzhagalov
I
, Dunkle
A
, He
Y.-W.
. The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages
. J Immunol
. 2008
;181
(1
):521
-528
.84.
Wensveen
FM
, van Gisbergen
KPJM
, Derks
IAM
, et al. Apoptosis threshold set by Noxa and Mcl-1 after T cell activation regulates competitive selection of high-affinity clones
. Immunity
. 2010
;32
(6
):754
-765
.85.
Thomas
LW
, Lam
C
, Edwards
SW
. Mcl-1; the molecular regulation of protein function
. FEBS Lett
. 2010
;584
(14
):2981
-2989
.86.
Maurer
U
, Charvet
C
, Wagman
AS
, Dejardin
E
, Green
DR
. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1
. Mol Cell
. 2006
;21
(6
):749
-760
.87.
Miklja
Z
, Yadav
VN
, Cartaxo
RT
, et al. Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma
. J Clin Invest
. 2020
;130
(10
):5313
-5325
.88.
Mills
JR
, Hippo
Y
, Robert
F
, et al. mTORC1 promotes survival through translational control of Mcl-1
. Proc Natl Acad Sci USA
. 2008
;105
(31
):10853
-10858
.89.
Campbell
KJ
, Mason
SM
, Winder
ML
, et al. Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic function
. Cell Death Differ
. 2021
;28
(9
):2589
-2600
.90.
Nangia
V
, Siddiqui
FM
, Caenepeel
S
, et al. Exploiting MCL1 dependency with combination MEK + MCL1 inhibitors leads to induction of apoptosis and tumor regression in KRAS-mutant non-small cell lung cancer
. Cancer Discov
. 2018
;8
(12
):1598
-1613
.91.
Roberts
AW
, Wei
AH
, Huang
DCS
. BCL2 and MCL1 inhibitors for hematologic malignancies
. Blood
. 2021
;138
(13
):1120
-1136
.92.
Opferman
JT
, Letai
A
, Beard
C
, et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1
. Nature
. 2003
;426
(6967
):671
-676
.93.
Opferman
JT
, Iwasaki
H
, Ong
CC
, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells
. Science
. 2005
;307
(5712
):1101
-1104
.94.
Arbour
N
, Vanderluit
JL
, Le Grand
JN
, et al. Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage
. J Neurosci
. 2008
;28
(24
):6068
-6078
.95.
Liu
H
, Eksarko
P
, Temkin
V
, et al. Mcl-1 is essential for the survival of synovial fibroblasts in rheumatoid arthritis
. J Immunol
. 2005
;175
(12
):8337
-8345
.© 2022 by The American Society of Hematology
2022
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal